Building a robust pipeline to fight cancer
Current ADC and mAb developments
VX-A901 - A novel therapeutic option for elderly AML patients
Acute myeloid leukemia (AML) is an aggressive cancer that mainly affects the elderly. Despite improvements, younger and fitter patients still tend to benefit more than older and less fit individuals. Treatment options for elderly patients and those who are not fit for intensive chemotherapy and stem cell transplantation are limited. The need for better therapies for older and unfit patients is growing.
FLT-3 is overexpressed in the majority of AML blasts
VX-A901 binds to primary blasts irrespective of mutation in FLT3
Optimized Fc-part induces ADCC via strong binding to NK cells
Distinct and complementary Mode of Action
VX-A901 can be combined with the first line of therapy
No ADCC effect on FLT-low expressing healthy bone marrow-derived HSPCs
Promising phase-1 clinical trial results
VX-A901 is safe and well tolerated in AML patients
Promising signs of monotherapy efficacy even in heavily pre-treated patients
Your partner from target to antibody to ADC
Our unique antibody screening platform and proprietary ADC technology enable us to create highly innovative targeted biotherapeutics.VERAXA has a proprietary pipeline and has also partnered with pharmaceutical and biotechnological companies to accelerate the development of superior ADCs and functional mAbs.We are open to strategic partnership that support our core strategy and increase the value of a growing drug pipeline.
If you are interested in partnering with us
We are your partner from target to antibody to ADC. Our unique antibody screening platform and proprietary ADC technology enable us to help you create the best targeted biotherapeutics for your application.
With partnership models tailored to your needs, we can join you at any step of your development journey, whether you are starting out with a target or are looking for a bioconjugation partner.